CAI Stock — Caris Life Sciences, Inc.

Caris Life Sciences, Inc. (CAI)

Updated October 16, 2026.

CAI is a Stock. Total return is 9.1% over the past 1.3 years, 20.8 points behind SPY at 29.9%.

Caris Life Sciences is an artificial intelligence-driven biotechnology company that develops and commercializes molecular profiling services for precision oncology and cancer detection. The company offers a portfolio of molecular intelligence products including tissue and blood-based sequencing platforms, multi-cancer early detection solutions, and minimal residual disease testing, along with research and development services to biopharmaceutical customers. The company does not currently distribute dividends.

CAI performance versus SPY

Price and return data through 2026-10-16.

Total return is 9.1% over the past 1.3 years, 20.8 points behind SPY at 29.9%. Its deepest 1-year drawdown was 54.5%.

CAI key facts

Asset type

Stock

Asset class

Equity

Inception date

06/18/2025

Distribution frequency

None

Last close

$30.56 (as of 2026-10-16)

Market cap

$8,638,722,039

Average volume

2730078.0

Payout ratio

0.0%

P/E ratio

18.08

Forward P/E

43.29

EPS

$1.69

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CAI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 54.5%.

Who may consider CAI — and who may not

It is a weaker fit for investors who need monthly cash flow (CAI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CAI

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions